Cautious Outlook on Vertex Pharmaceuticals Amid Journavx Approval and Pricing Concerns
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
pharmaphorum28m
Vertex bags FDA okay for its non-opioid pain drug
Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...
FDA Approves First New Non-Opiod Painkiller in Decades
Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.
WSAV Savannah on MSN45m
New type of non-opioid pain medication approved by FDA
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
US FDA approves new painkiller Journavx as alternative to opioids
US Federal officials have approved a new pain pill by Vertex Pharmaceuticals called Journavx, aimed at reducing addiction and ...
Vertex Pharmaceuticals price target raised to $435 from $418 at Barclays
Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $435 from $418 and keeps an Equal Weight rating ...
New non-opioid painkiller approved by US health agency
A new type of non-opioid painkiller, aimed at treating short-term pain in adults, has been approved by the US Food and Drug Administration (FDA). The drug suzetrigine, known by its brand name Journavx ...
Erie News Now17m
5 Things to know for Jan. 31: Plane collision, Confirmation hearings, Pain medicine, Japan sinkhole, FireAid benefit concerts
Here’s what else you need to know to Get Up to Speed and On with Your Day. Three of President Donald Trump’s most controversial picks for his Cabinet and key administration roles were grilled during ...